Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Gyre Therapeutics (GYRE) over the last 6 years, with Q3 2025 value amounting to $200000.0.

  • Gyre Therapeutics' Receivables - Other fell 8461.54% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $200000.0, marking a year-over-year decrease of 8461.54%. This contributed to the annual value of $5.0 million for FY2024, which is N/A changed from last year.
  • Per Gyre Therapeutics' latest filing, its Receivables - Other stood at $200000.0 for Q3 2025, which was down 8461.54% from $200000.0 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Receivables - Other registered a high of $5.0 million during Q4 2024, and its lowest value of $200000.0 during Q2 2025.
  • Its 3-year average for Receivables - Other is $1.2 million, with a median of $1.2 million in 2023.
  • In the last 5 years, Gyre Therapeutics' Receivables - Other skyrocketed by 33333.33% in 2024 and then plummeted by 8461.54% in 2025.
  • Over the past 3 years, Gyre Therapeutics' Receivables - Other (Quarter) stood at $1.2 million in 2023, then surged by 313.42% to $5.0 million in 2024, then plummeted by 95.97% to $200000.0 in 2025.
  • Its last three reported values are $200000.0 in Q3 2025, $200000.0 for Q2 2025, and $230000.0 during Q1 2025.